Table 2

Log-rank, univariate and multivariate associations with OS for clinical variables and genomic characteristics for 176 primary HER2+ tumors

Investigated covariate^a

Number tumors

Log-rank

P

Univariate

P

Multivariate

P^b

ER+ vs. ER-

64/112

0.96

0.96

0.79

LN+ vs. LN-

110/65

4 × 10^-6 ***

9 × 10^-6 ***

0.0002***

Size >20 mm vs. ≤ 20 mm

122/49

0.002**

0.002**

0.02*

Histological grade 3 vs. 1 and 2

37/26

0.91

0.91

0.83

Age <50 vs. ≥50 years

73/103

0.22

0.23

0.77

DNA Aneuploid vs. Diploid

106/37

0.001**

0.001**

0.005**

DNA Aneuploid vs. Diploid ER+

37/11

0.008**

0.02*

0.07

DNA Aneuploid vs. Diploid ER-

69/26

0.05*

0.05*

0.06

Recurrent 17q amplification, yes vs. no

70/106

0.17

0.17

0.13

Recurrent amplification excluding 17q, yes vs. no

76/100

0.75

0.75

0.7

Firestorm pattern, yes vs. no

78/98

0.27

0.28

0.58

High FGA vs. low FGA^c

42/46

0.08

0.09

0.25

High FGA vs. low FGA ER+ tumors^c

18/17

0.09

0.09

0.26

High FGA vs. low FGA ER- tumors^c

24/29

0.37

0.37

0.55

^a Variables with worst outcome highlighted in bold for covariates significantly associated with OS.^b Multivariate analysis included LN status and stratified tumor size besides the tested covariate.^c High and Low FGA defined as >75^th percentile and <25^th percentile of all FGA values respectively.

*: Significant at P < 0.05

**: Significant at P < 0.01

***: Significant at P < 0.001

Staaf et al. Breast Cancer Research 2010 12:R25   doi:10.1186/bcr2568